Finally, an increased concentration of plasma EVs exposing complement activation particles, such as C1q, or activator molecules such as reactive C protein (CRP) or serum amyloid‐P (SAP), have also been reported to be increased in RA, remaining unchanged despite intensive anti‐rheumatic treatment.109. This evidence concerns the gene CRP and rheumatoid arthritis.